New findings from VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM), published in ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today ...

Study will highlight novel iNKT cell-based combinations in checkpoint-refractory diseaseData expected to inform immune modulation, treatment ...

BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced a ...

The FDA has granted Fast Track Designation to CTIM-76, a claudin-6 (CLDN6) x CD3 T cell engaging bispecific antibody, for the ...

How can cancer cells be targeted without damaging healthy tissue? This is one of the major challenges facing oncology today.

Orphan Drug Designation is a key incentive established by the EMA to facilitate the development and authorisation of ...

"We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company's evolution," said Thomas Fuchs, CEO, Mosaic Therapeutics. "His deep expertis ...

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on cancer diagnostics and targeted therapeutics, will present findings today related ...

Tango Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of precision oncology therapies. The company leverages synthetic lethality and genetic ...